Professional Marketing briefs: May 2014

Share this article:
Teva's exrended-release painkiller has entered Phase-III testing
Professional Marketing briefs: May 2014

The top 34 UK drug companies paid medical professionals around $64 million dollars last year, down from $66 ­million the year before, for services that included speeches, medical study participation and third-party meeting sponsorships, reports PMLive.

Teva announced April 1 that the Supreme Court will hear its appeal in a move to delay generic competition for the drugmaker's multiple sclerosis treatment Copaxone. A win in the case would extend Teva's patent through September 2015; a loss would mean that generics could begin pouring in before summer—the patent is set to expire this month.

The cost of maintaining sales reps has gone up since before the recession, but the Wall Street Journal says it's not by much: between $125,000 to $200,000 annually for a single primary care rep. The Journal says the uptick has been slight because reps now travel less, have “fewer extravagant meetings,” and technology costs less. WSJ research materials also note that the average cost of each primary care physician detail is around $210 if it includes samples, $178 if it doesn't, while detailing a specialist could run around $285 with samples, and $267 without.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?